Extraskelatal Myxoid Chondrosarcoma of Leg in A 35 Years Old Female: Report of A Rare Malignant Tumor of Uncertain Differentiation

Dr. Rubeena Naz Mohroo, M.D1, Dr. Mohammad Jaseem Hassan, M.D2, Dr. Safia Rana, DCP, DNB3, Dr. Sabina Khan, M.D4, Dr. Sujata Jetley, M.D5

1Demonstrator, 2Associate Professor, 3Assistant Professor, 4Professor, Department of Pathology, Hamdard Institute of Medical Sciences and Research (HIMSR), Jamia Hamdard, New Delhi, 110062, India

DOI: 10.36348/sjpm.2020.v05i06.001 | Received: 21.05.2020 | Accepted: 31.05.2020 | Published: 06.06.2020

Abstract

Extraskelatal myxoid chondrosarcoma is a rare malignant soft tissue tumor of uncertain differentiation, constituting less than 3% of all soft tissue sarcomas. This low grade malignant tumor with high recurrence and metastatic potential, occurs predominantly in proximal extremities and limb girdles of males with thigh being the most common location. Here we present a case in a 35 years old female, who presented with pain and large swelling of around 8cm in lateral side of left leg since five months. Wide local excision of the tumor was done and on histopathological examination, a diagnosis of Extraskelatal myxoid chondrosarcoma was rendered. On Immunohistochemistry the tumor cells showed reactivity for Vimentin, S100 and NSE and was non-reactive for CK. Thus our histopathological diagnosis was reconfirmed by immunohistochemistry. Despite high incidence of local recurrence and metastasis, ESMC has an excellent overall survival rate.

Keywords: Extraskelatal, Low grade sarcoma, Malignant potential, Myxoid, Uncertain differentiation.

Copyright © 2020: This is an open-access article distributed under the terms of the Creative Commons Attribution license which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use (NonCommercial, or CC-BY-NC) provided the original author and sources are credited.

INTRODUCTION

Soft tissue sarcomas accounts for less than 1% of the overall burden of malignant tumors in human being [1]. Extraskelatal myxoid chondrosarcoma (ESMC) is a very rare soft tissue tumor, which accounts for less than 3% of all soft tissue sarcomas [1]. Although first described by Stout and Verner in 1953, it was Enzinger and Shiraki who described ESMC as a distinct clinicopathological entity in 1972 in their study of 34 cases [2, 3]. The 2002 edition of WHO classification of tumors of soft tissue and bones recognised ESMC as a specific entity and categorised it in malignant category of tumor of uncertain differentiation [4]. As per WHO, ESMC is characterised by “a multinodular architecture, abundant myxoid matrix, and malignant chondroblast-like cells arranged in cords, clusters, or delicate networks” [4]. However contrary to its name, no convincing evidence of cartilaginous differentiation is seen in ESMC [5], hence it is different from Extraskelatal mesenchymal chondrosarcoma. ESMC primarily occurs in 5th to 7th decade of life and seen twice as commonly in males than females. Deep soft tissues of the proximal extremities and limb girdles are the most common location for this tumor, however they can also be seen in trunk, paraspinal region, foot, and head and neck region. Intracranial location, fingers, retroperitoneum, pleura and bone is rare site for this tumor [4]. Here we report a case of ESMC in a 35 years old female who presented with swelling and pain in left lower leg since five months.

CASE HISTORY

A 35 years old female patient presented with swelling and pain in left lower leg since five months. Swelling was present at the lateral aspect of the left leg and appears firm, non-tender, non-mobile, non-pulsatile, about 9x5cm in size with normal overlying skin and normal adjacent underlying structure. MRI of the left leg shows well defined encapsulated, lobulated soft tissue mass lesion in the peroneus muscle belly at left mid leg laterally, with no neurovascular or bony involvement. The patient was admitted and wide local excision of the mass was planned. Pre-operative hematological and biochemical tests were within normal limit. The mass was excised and sent for histopathological examination. On gross examination, an encapsulated elongated grey white to grey brown soft to firm mass with nodular external surface measuring 8x4x2.5 cm was received which on cut section shows multiple gelatinous nodules separated by fibrous septa. (Fig-1A & 1B) Areas of hemorrhage was also seen. Microscopic examination of the mass showed...
an encapsulated multinodular architecture in which tumor cells are arranged in lobules and cords, filled with myxoid or chondromyxoid material and separated by fibrous tissue. (Fig-2A to 2D) Tumor cells were moderately pleomorphic, round to oval in shape with irregular nuclei, open chromatin, prominent nucleoli and eosinophilic to clear cytoplasm. Mitosis was sparse. Thus based on these features the diagnosis of Extraskeletal myxoid chondrosarcoma (ESMC) was rendered histopathologically. On immunohistochemistry (IHC) the tumor cells showed positivity for Vimentin, S100 and NSE, and was negative for CK. Thus IHC reconfirms our histopathological diagnosis of ESMC.

DISCUSSION

Extra skeletal myxoid chondrosarcoma is rare, slow growing, low grade malignant soft tissue tumour with high local recurrence and metastatic potential. ESMC occurs mainly in deep soft tissues of the proximal extremities and limb girdles in individuals of 50-70 years of age group [4]. Thigh is the most common location for this tumor, however this tumor can be present in rare locations like head and neck region, trunk, paraspinal region, intracranial regions etc. as well [4]. Our patient was a 35 years old female who presented with pain and swelling of left leg. Sayal NR et al., reported a case of ESMC of neck in a 65 years old male who presented with large neck mass occluding the airway and causing dyspnoea [6]. Zhang L et al. in
their 12 years of study reported 13 cases of ESMC. In their study in addition to extremities they have also reported one case each in spinal canal, nasopharynx, wall of chest, right lower jaw and right lumbosacral region of the spine [5]. Drilon AD et al., studied the clinical behaviour and treatment responses of 87 cases of ESMC in their retrospective review study over a period of 33 years. In their study out of 87 cases of ESMC, 53 cases were present in lower extremity, 15 cases were seen in upper extremity, 11 cases were reported in abdomen, retroperitoneum and pelvic area, 5 cases were seen in chest wall & abdominal wall and one case was seen in intrathoracic region and one case was reported from head and neck region [7], Rao P et al., reported a case of thoracic intradural ESMC in a 29 years old male patient [8].

Microscopically conventional well differentiated ESMC has characteristic multinodular architecture in which circumscribed tumor cells filled will myxoid/chondromyxoid stroma is separated by fibrous septa [4]. The tumor cells are usually arranged in cords and clusters and have round to oval nuclei with inconspicuous nuclei and moderate amount of eosinophilic granular to vacuolated cytoplasm. The mitotic activity is usually low. Areas of hemorrhage are also seen [4]. Our case show all the features of conventional ESMC. The cellular variant of ESMC is characterised by high cellularity with closely spaced epithelioid cells with minimal myxoid stroma [4]. High grade ESMC is characterised by sheets of anaplastic epithelioid cells with fibrosarcomatous area, high mitotic activity and large areas of necrosis without myxoid/chondromyxoid stroma [4].

ESMC has no distinct diagnostic immunohistochemical profile. However vimentin is generally expressed in 100% of cases [4]. Immunoreactivity for Neuron- specific enolase is seen in 100% cases, Synaptophysin in 87% cases, S100 in 50% cases and Epithelial membrane antigen in 25% of cases [9]. Our case showed positivity for Vimentin, S100 and NSE.

Utrastructural study of ESMC by Hisaoka M et al., confirms the neuroendocrine differentiation of ESMC. They demonstrated neuron-specific microtubule-related proteins MAP-2 and class III tubulin in ESMC [10]. Goh YW et al., also confirms the neuroendocrine differentiation of ESMC by immunophenotypic and ultrastructural study [9]. Both these studies confirms that ESMC is a specific entity and ruling out the possibility of chondrocytic or prechondrocytic origin of ESMC [9, 10].

Ancillary cytogenetic and molecular studies can be extremely useful in establishing a definitive diagnosis for ESMC. ESMC is marked by a reciprocal translocation t (9;22) (q22; q12) generating a EWS/NR4A3 gene fusion, in approximately 50% of cases [4, 7]. This translocations result in fusion gene products, which leads to tumorigenesis by causing alterations in cellular growth and differentiation [7].

ESMC was graded as grade 2/3 tumor by the French Federation of Cancer Centres (FNCLCC) [7]. Treatment of ESMC consist of wide local excision for localised disease, while systemic chemotherapy is recommended for metastatic disease. Despite surgical intervention, a high rate of local recurrence in the range of 14-64% is reported by various authors [7], while metastatic disease is reported in upto 46% of cases [8]. Lung is the most common site for metastasis, while extrapulmonary metastasis most commonly reported in soft tissues, lymph nodes and bones [8]. Despite high incidence of local recurrence and metastasis, excellent overall survival for ESMC is reported by various authors. The 5 year survival rate was reported between 82-100% [7, 11, 12], 10 year survival rate was reported between 65-88% [7, 11, 12], and 15 years survival rate was reported between 58-60% [7, 11]. Unfavourable prognostic factors include male sex, older age (>50 years), large tumor size (≥10cm), deep location of the tumor, proximal tumor site, inadequate initial surgery, cellular tumor, presence of anaplasia, high mitotic count and high Ki-67 expression [11, 13].

CONCLUSION

ESMC is a very rare low grade malignant soft tissue tumor, which is recognised as a specific entity and categorised in malignant category of tumor of uncertain differentiation by WHO. Surgical intervention in the form of WLE is the only satisfactory cure of localised tumor, which reduces the chance of local disease recurrence and thus improved the overall survival of the patient. Despite the high local recurrence rate and metastatic potential, ESMC has an excellent overall survival rate with 10 year survival rate in the range of 65-88%.

REFERENCES


